Serum eosinophil cationic protein during treatment of asthma in children
View abstract on PubMed
Summary
This summary is machine-generated.Serum eosinophil cationic protein (ECP) levels decreased in children with asthma after treatment with inhaled budesonide or sodium cromoglycate. Higher baseline ECP correlated with a greater decrease, indicating potential for ECP as an asthma biomarker.
Area Of Science
- Pediatric Pulmonology
- Allergy and Immunology
- Pharmacology
Background
- Serum eosinophil cationic protein (ECP) is a proposed marker for bronchial inflammation and hyperreactivity in asthma.
- Asthma management often involves assessing inflammatory markers to guide treatment.
Purpose Of The Study
- To evaluate changes in serum ECP levels in children with asthma following treatment with inhaled budesonide or sodium cromoglycate (SCG).
- To explore the relationship between baseline ECP levels and treatment response.
Main Methods
- Serum ECP levels were measured before and at 1 and 5 months after initiating treatment.
- Inhaled budesonide (800 mcg/m2 initially, then 400 mcg/m2) or SCG (7 children) was administered daily.
- ECP levels were quantified using radioimmunoassay.
Main Results
- A statistically significant decrease in serum ECP was observed over 5 months of treatment for both groups combined (p=0.020) and the budesonide group (p=0.049).
- A strong inverse correlation was found between initial ECP levels and the magnitude of ECP decrease during treatment in both budesonide (r=-0.697) and SCG (r=-0.893) groups.
- No significant correlation was found between ECP levels/changes and forced expiratory volume in 1 second percentage (FEV1%) or changes therein.
Conclusions
- Inhaled budesonide and SCG treatments led to a significant reduction in serum ECP levels in children with asthma.
- The study suggests serum ECP may be a sensitive indicator of treatment response in pediatric asthma.
- Further research is needed to establish the clinical utility of these ECP level changes in asthma management.